Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization

Hans Peter Hammes, Michael Brownlee, Alfred Jonzcyk, Arne Sutter, Klaus T. Preissner

Research output: Contribution to journalArticle

299 Citations (Scopus)

Abstract

Retinal neovascularization is a major cause of blindness in such disorders as retinopathy of prematurity, proliferative diabetic retinopathy and senile macular degeneration. Because ligation of vitronectin receptor-type integrins appears to be required for the survival and maturation of newly formed but not quiescent blood vessels in several vascular beds including the retina, blockade of this downstream adhesion receptor system was investigated. In a mouse model of hypoxia-induced retinal neovascularization twice daily administration of 1 to 20 mg cyclic α(v)-integrin antagonist peptide per kilogram of body weight reduced capillary proliferation in a dose-dependent fashion - maximum 76% - without obvious side effects. A cyclic control peptide displayed no inhibitory effect on neovascularization. These findings indicate that systemic application of vitronectin receptor antagonists appears to be clinically feasible and is efficient in preventing retinal neovascularization and superior to cytokine-blocking strategies.

Original languageEnglish (US)
Pages (from-to)529-533
Number of pages5
JournalNature Medicine
Volume2
Issue number5
DOIs
StatePublished - 1996

Fingerprint

Integrin alphaVbeta3
Retinal Neovascularization
Cyclic Peptides
Subcutaneous Injections
Integrins
Peptides
Blood Vessels
Blood vessels
Retinopathy of Prematurity
Diabetic Retinopathy
Blindness
Cytokines
Ligation
Retina
Body Weight

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. / Hammes, Hans Peter; Brownlee, Michael; Jonzcyk, Alfred; Sutter, Arne; Preissner, Klaus T.

In: Nature Medicine, Vol. 2, No. 5, 1996, p. 529-533.

Research output: Contribution to journalArticle

Hammes, Hans Peter ; Brownlee, Michael ; Jonzcyk, Alfred ; Sutter, Arne ; Preissner, Klaus T. / Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. In: Nature Medicine. 1996 ; Vol. 2, No. 5. pp. 529-533.
@article{bdc677657ba74376a39ff88503bda816,
title = "Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization",
abstract = "Retinal neovascularization is a major cause of blindness in such disorders as retinopathy of prematurity, proliferative diabetic retinopathy and senile macular degeneration. Because ligation of vitronectin receptor-type integrins appears to be required for the survival and maturation of newly formed but not quiescent blood vessels in several vascular beds including the retina, blockade of this downstream adhesion receptor system was investigated. In a mouse model of hypoxia-induced retinal neovascularization twice daily administration of 1 to 20 mg cyclic α(v)-integrin antagonist peptide per kilogram of body weight reduced capillary proliferation in a dose-dependent fashion - maximum 76{\%} - without obvious side effects. A cyclic control peptide displayed no inhibitory effect on neovascularization. These findings indicate that systemic application of vitronectin receptor antagonists appears to be clinically feasible and is efficient in preventing retinal neovascularization and superior to cytokine-blocking strategies.",
author = "Hammes, {Hans Peter} and Michael Brownlee and Alfred Jonzcyk and Arne Sutter and Preissner, {Klaus T.}",
year = "1996",
doi = "10.1038/nm0596-529",
language = "English (US)",
volume = "2",
pages = "529--533",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization

AU - Hammes, Hans Peter

AU - Brownlee, Michael

AU - Jonzcyk, Alfred

AU - Sutter, Arne

AU - Preissner, Klaus T.

PY - 1996

Y1 - 1996

N2 - Retinal neovascularization is a major cause of blindness in such disorders as retinopathy of prematurity, proliferative diabetic retinopathy and senile macular degeneration. Because ligation of vitronectin receptor-type integrins appears to be required for the survival and maturation of newly formed but not quiescent blood vessels in several vascular beds including the retina, blockade of this downstream adhesion receptor system was investigated. In a mouse model of hypoxia-induced retinal neovascularization twice daily administration of 1 to 20 mg cyclic α(v)-integrin antagonist peptide per kilogram of body weight reduced capillary proliferation in a dose-dependent fashion - maximum 76% - without obvious side effects. A cyclic control peptide displayed no inhibitory effect on neovascularization. These findings indicate that systemic application of vitronectin receptor antagonists appears to be clinically feasible and is efficient in preventing retinal neovascularization and superior to cytokine-blocking strategies.

AB - Retinal neovascularization is a major cause of blindness in such disorders as retinopathy of prematurity, proliferative diabetic retinopathy and senile macular degeneration. Because ligation of vitronectin receptor-type integrins appears to be required for the survival and maturation of newly formed but not quiescent blood vessels in several vascular beds including the retina, blockade of this downstream adhesion receptor system was investigated. In a mouse model of hypoxia-induced retinal neovascularization twice daily administration of 1 to 20 mg cyclic α(v)-integrin antagonist peptide per kilogram of body weight reduced capillary proliferation in a dose-dependent fashion - maximum 76% - without obvious side effects. A cyclic control peptide displayed no inhibitory effect on neovascularization. These findings indicate that systemic application of vitronectin receptor antagonists appears to be clinically feasible and is efficient in preventing retinal neovascularization and superior to cytokine-blocking strategies.

UR - http://www.scopus.com/inward/record.url?scp=0029925079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029925079&partnerID=8YFLogxK

U2 - 10.1038/nm0596-529

DO - 10.1038/nm0596-529

M3 - Article

C2 - 8616710

AN - SCOPUS:0029925079

VL - 2

SP - 529

EP - 533

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 5

ER -